# Sangel Capital

Sangel Capital is a Private Equity based in Shenzhen, China.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Shenzhen, China
- **Region:** Asia
- **Address:** Shenzhen, China
- **Assets under management:** Undisclosed
- **Website:** www.sangelvc.com

## Regulatory record

- **Reports private funds:** No

## About

Sangel Capital is a venture capital and business finance firm based in Shenzhen, China. It invests in high-tech enterprises in China and Western countries, focusing on sectors such as biomedicine, medical devices, healthcare, and biotech. The firm has made 57 investments, including a Series A investment in Proviva Therapeutics on March 05, 2024, and has facilitated 4 portfolio exits, including the sale of Ultivue on October 09, 2024.

## Questions

### What investment stages does Sangel Capital typically target?

Sangel Capital describes its strategy as covering early-stage, seed, start-up, and growth-stage venture investments. The firm has not published specific check sizes, ownership targets, or stage allocation breakdowns, so precise preferences across these stages cannot be confirmed from public sources.

### Which sectors does Sangel Capital focus on?

Sangel Capital has not published a sector-specific investment thesis or any named portfolio companies. Based on its Shenzhen location and the city's concentration of hardware, electronics, and deep-tech startups, exposure to these sectors is plausible but unconfirmed.

## Related profiles

- [Sangam Ventures](https://altss.com/profile/sangam-ventures)
- [Sangha Capital](https://altss.com/profile/sangha-capital)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/sangel-capital

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology